HMGB1: A Potential Therapeutic Target for Non-Small Cell Lung Cancer

  title={HMGB1: A Potential Therapeutic Target for Non-Small Cell Lung Cancer},
  author={Zhenbo Tu and Anlin Feng and Ommega Internationals},
Recent studies have found HMGB1 as a potential and valuable bio-marker for NSCLC. Many targeted therapies have been developed with effective clinical proofs; however treatment responses are typically short-lived because of the frequent mutation of target genes. HMGB1 which has been targeted in several cancer therapies for its conservative feature would possess a potential clinical value for NSCLC treatment. 

Tables from this paper

Erlotinib in non-small cell lung cancer treatment: current status and future development.

Elotinib has shown a significant improvement in median survival, quality of life, and related symptoms in an unselected population of advanced and metastatic NSCLC patients in the second- or third-line setting, and has significant antitumor activity in first-line treatment.

Genomic alterations in lung adenocarcinoma.

The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer

HMGB1 is a potential biomarker to predict progression and survival of NSCLC, especially of ADC types, and was detected that the mitogen-activated protein kinases (MAPK), apoptosis and cell cycle signaling pathways were the key pathways that varied during HMGB1 up-regulation in ADC.

Targeting VEGF in lung cancer

The authors review the data that led to the approval of bevacizumab, a monoclonal antibody against VEGF, in the treatment of lung cancer and the key results from a number of Phase II and Phase III trials involving other anti-angiogenic agents being studied in NSCLC.

Overview of gefitinib in non-small cell lung cancer: an Asian perspective.

  • Haiyi Jiang
  • Medicine, Biology
    Japanese journal of clinical oncology
  • 2009
Clinical experience with the EGFR-TKI gefitinib in Asian patients with NSCLC will be reviewed, both in patients who have previously failed chemotherapy and in the first-line setting (gefitinib is

Ethyl pyruvate administration inhibits hepatic tumor growth

EP inhibition of tumor growth in the liver was mediated by tumor (induction of apoptosis) and host (decreased inflammation) effects, suggesting that EP administration may have a therapeutic role in the treatment of cancer in conjunction with other therapeutic agents.

HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells

High-mobility group box 1 (HMGB1), the best characterized damage-associated molecular pattern, was released from leukemia cell lines after chemotherapy-induced cytotoxicity and activated autophagy to protect against injury and suggest that HMGB1 release after chemotherapy is a critical regulator of autophamy and a potential drug target for therapeutic interventions in leukemia.

Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells

It is suggested that quercetin plays an important role in modulating RAGE and HMGB1 signaling and induces apoptotic cell death in MCF‐7 cells.

Immunogenic death of colon cancer cells treated with oxaliplatin

OXP induces immunogenic death of CRC cells, and this effect determines its therapeutic efficacy in CRC patients, and both oxaliplatin and cisplatin were equally efficient in triggering HMGB1 release.

High-mobility group box 1 and cancer.